Nkarta NKTX 深 沪
等待开盘 09-01 09:30:00 美东时间
2.71
-0.050
-1.81%
华盛通- 最 高2.75
- 今 开2.73
- 成交量 47.76万股
- 最 低 2.6511
- 昨 收 2.76
- 总市值 1.94亿
- 52周最高 3.72
- 市盈率 静 --
- 换手率 0.67%
- 52周最低 1.70
- 委 比 -41.89%
- 总股本 7162.48万
- 历史最高 79.16
- 量 比 1.12
- 振 幅 3.58%
- 历史最低 1.28
- 每 手 1
- 风险率 0.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
HC Wainwright & Co. Maintains Buy on Nkarta, Lowers Price Target to $14
HC Wainwright & Co. analyst Emily Bodnar maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $16 to $14.
08-11 20:34
Nkarta Q2 EPS $(0.54) Misses $(0.38) Estimate
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.38) by 42.11 percent. This is a 74.19 percent decrease over losses of $(0.31) per share from the same period last year.
08-11 05:04
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Nkarta, Inc. will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. Nkarta President Nadir Mahmood will discuss updates on the company’s investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases during a fireside chat at 2 p.m. ET. The discussion will be webcast live and available for replay on Nkarta’s investor website for 90 days. Nkarta is a clinical-stage biotech company developi...
06-26 12:45
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Needham Reiterates Buy on Nkarta, Maintains $11 Price Target
Needham analyst Gil Blum reiterates Nkarta (NASDAQ:NKTX) with a Buy and maintains $11 price target.
05-13 18:45
Nkarta Q1 EPS $(0.37), Inline
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 13.95 percent increase over losses of $(0.43) per share from the same period last year.
05-13 04:33
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Nkarta reported Q1 2026 financial results with a cash balance of $266.7 million, supporting operations into 2029. Enrollment continues in Ntrust-1 and Ntrust-2 trials at 4 billion cell dose levels. FDA agreement allows outpatient dosing and expansion to community settings. Initial clinical data expected in 2026. R&D expenses were $25.0 million, G&A expenses $5.9 million, resulting in a net loss of $27.8 million.
05-12 20:01
